A5083116317- Hepatocellular Carcinoma Treatment and Prognosis
- Neuroblastoma Research and Treatments
- Glioma Diagnosis and Treatment
- Cancer, Lipids, and Metabolism
- Lung Cancer Research Studies
- Neuroendocrine Tumor Research Advances
- Liver Disease Diagnosis and Treatment
- Polyomavirus and related diseases
- Renal cell carcinoma treatment
- Renal and related cancers
- Inflammatory Biomarkers in Disease Prognosis
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Cancer Genomics and Diagnostics
- Gestational Trophoblastic Disease Studies
- Virus-based gene therapy research
- Cancer Immunotherapy and Biomarkers
- Cancer therapeutics and mechanisms
- Pancreatic and Hepatic Oncology Research
- Brain Metastases and Treatment
- Liver Disease and Transplantation
- Liver physiology and pathology
- Advanced Radiotherapy Techniques
Centre Eugène Marquis
2018-2025
National Yang Ming Chiao Tung University
2023
Taipei Veterans General Hospital
2023
University of Genoa
2023
Imperial College London
2023
Ospedale Policlinico San Martino
2023
Humanitas University
2023
Background: Selective internal radiation therapy (SIRT) is an innovative treatment of hepatocellular carcinoma (HCC). The albumin-bilirubin (ALBI) score was designed to better evaluate liver functions in HCC. Methods: We studied, retrospectively, data from patients treated with SIRT for primary endpoint the occurrence radioembolization-induced disease (REILD). secondary overall survival (OS). Results: 222 were studied. ALBI grade 1 had significantly less REILD (3.4%) after first than 2 or 3...
Abstract Background: Virus-associated tumors, characterized by immune evasion and angiogenic signaling, remain a therapeutic challenge. Human papillomavirus (HPV)-associated cancers such as cervical, anal, oropharyngeal represent significant subset of virus-associated tumors are mediated viral oncoproteins E6 E7. Toll-like receptor 7/8 (TLR7/8) agonists EIK1001 have been shown to activate innate pathways, enhancing antigen presentation inducing robust adaptive response. This is particularly...
6050 Background: Anti-PD1 therapies improve overall survival (OS) in recurrent/metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN), but only a minority patients (pts) achieve durable responses. The mechanisms driving resistance to anti-PD1 SCCHN remain poorly understood. Methods: Using IMMUcan multi-omics workflow combining WES, RNAseq, multiplex immunofluorescence Imaging mass cytometry, we characterized molecular immune profiles R/M progressing on treatment compared them...
Background Selective internal radiation therapy (SIRT) is applied to hepatocellular carcinoma (HCC), a disease with increased incidence in the elderly. However, SIRT has rarely been specifically studied elderly population. The aim of this study was investigate efficacy and safety HCC patients. Methods We retrospectively data from patients treated for HCC. Clinical laboratory were retrieved. used 70-years old as threshold between younger populations, compare outcomes. Results A total 222...
e22008 Background: Oral temozolomide capsule is approved for the treatment of glioma and malignant glioblastoma in adults Europe children over 3-years. As recommended by international pediatric medical associations, also used high-risk relapsed or refractory neuroblastoma, a solid tumor affecting young children. Nevertheless, capsules are not adapted to population leading caregivers handle capsules, which bears major risks (i.e. dose inaccuracy, instability exposure cytotoxic drug). To...
Temozolomide (TMZ) oral suspension (Ped-TMZ, KIZFIZO®) is being developed for the treatment of relapsed or refractory neuroblastoma, a rare cancer affecting infants and young children. The study assessed safety bioequivalence this novel pediatric formulation with existing TMZ capsules. In vitro dissolution profiles were evaluated following European Medicines Agency "Guidelines on investigation Bioequivalence". phase I, multicenter, randomized, open-label, crossover, single-dose enrolled 36...